Evidence map›Paper›PMID 37591547›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2023

Do Bone Scans Overstage Disease Compared with PSMA PET at Initial Staging? An International Multicenter Retrospective Study with Masked Independent Readers.

Thomas A Hope, Matthias Benz, Fei Jiang, Daniel Thompson, Francesco Barbato, Roxana Juarez, Miguel Hernandez Pampaloni, Martin Allen-Auerbach, Pawan Gupta, Wolfgang P Fendler and 1 more

Open access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 30 citations in OpenAlex.

  1. Trial
  2. Automated lesion tracking and treatment response classification on [European journal of nuclear medicine and molecular imaging · 2026
    Article
  3. Article
  4. Review
  5. Sociodemographic disparities in prostate cancer imaging.Abdominal radiology (New York) · 2026
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. [European journal of nuclear medicine and molecular imaging · 2025
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Thomas A HopeDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California; thomas.hope@ucsf.edu.
Matthias BenzAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Fei JiangDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California; and.
Daniel ThompsonDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Francesco BarbatoDepartment of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium, University Hospital Essen, Essen, Germany.
Roxana JuarezDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Miguel Hernandez PampaloniDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Martin Allen-AuerbachAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Pawan GuptaAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Wolfgang P FendlerDepartment of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium, University Hospital Essen, Essen, Germany.
Jeremie CalaisAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
University of California, San Francisco · USDeutschen Konsortium für Translationale Krebsforschung · DEUniversity of Duisburg-Essen · DE

Funding

MELT: Modulation of PSMA Expression for Lutetium TherapyR01CA235741 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HOPE, THOMAS A · 2019 to 2025
$3.2M
Qualification and Harmonization of PET/MRI for Cancer Clinical TrialsR01CA212148 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HOPE, THOMAS, LAFOREST, RICHARD ANDRE · 2017 to 2022
$2.7M
NCI NIH HHS R01 CA212148NCI NIH HHS R01 CA235741
6 · The paper itself

Abstract

Prostate-specific membrane antigen (PSMA) PET has a higher accuracy than CT and bone scans to stage patients with prostate cancer. We do not understand how to apply clinical trial data based on conventional imaging to patients staged using PSMA PET. Therefore, we aimed to evaluate the ability of bone scans to detect osseous metastases using PSMA PET as a reference standard.

Indexed as

Bone NeoplasmsProstatic NeoplasmsGallium RadioisotopesHumansMalePositron Emission Tomography Computed TomographyReproducibility of ResultsRetrospective StudiesGallium Radioisotopesbone scansinitial stagingoncologyprostate cancerPSMA PETradiopharmaceuticals

Identifiers

PMID37591547
PMCPMC11927057
OpenAlexW4385951104

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.